ClinicalTrials.gg
CompletedNCT01134341Updated Dec 18, 2019

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

A Phase 1 interventional study of Pralatrexate Injection and Bexarotene Capsules in Cutaneous T-cell Lymphoma, Mycosis Fungoides and Sezary Syndrome, sponsored by Acrotech Biopharma Inc.. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-18.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States — 33 open to participants now, 45 under way, none of them phase 3. Lymphoma, T-Cell, Cutaneous · United States.

Enrollment
159th of 334
34 · median 33
Started
2010
with 21 others
Phase 1
159 of 434
10 open now
Registered
282nd of 434
by date

Among the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, this one is the 159th largest by enrollment of the 334 interventional ones that give a count, is one of 22 that started in 2010, is one of 159 in phase 1, and was the 282nd registered.

Lymphoma, T-Cell, Cutaneous

554 studies on the registry are indexed under Lymphoma, T-Cell, Cutaneous; 63 are open to participants now.

Browse Lymphoma, T-Cell, Cutaneous studies →

Open to participants now

33 of the 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 44 Lymphoma, T-Cell, Cutaneous studies recruiting now, 33 (75%) set no upper age limit and 6 (14%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 434 studies in Lymphoma, T-Cell, Cutaneous with a site in United States, or all of them as a file.
02

Study summary

This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.

Read the detailed description

This is a multi-center, dose-finding, Phase 1 study of pralatrexate plus bexarotene in patients who have relapsed or refractory CTCL.

Primary Objective(s):

  • Determine the maximum tolerated dose (MTD) and recommended dose of pralatrexate plus bexarotene with concurrent vitamin B12 and folic acid supplementation when administered to patients who have failed prior systemic treatment.

Secondary Objective(s):

  • Determine the safety profile of pralatrexate plus bexarotene when administered to patients with relapsed/refractory cutaneous T-cell lymphoma (CTCL).
  • Collect preliminary efficacy data.
  • Determine the pharmacokinetic (PK) profile of pralatrexate plus bexarotene in patients who underwent plasma PK sampling
03

Conditions studied

  • Cutaneous T-cell Lymphoma
  • Mycosis Fungoides
  • Sezary Syndrome
  • Primary Cutaneous Anaplastic Large Cell Lymphoma

Keywords

  • Relapsed
  • Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cutaneous T-cell lymphoma patients with subtypes of mycosis fungoides (MF) Stage IB or higher, Sézary syndrome, or primary cutaneous anaplastic large cell lymphoma who have failed a previous systemic treatment.
  • Patients must have received at least 1 previous systemic therapy, and either progressed or not tolerated their last prior treatment regimen.
  • Performance Status less than or equal to 2.
  • Adequate blood, liver, and kidney function as defined by laboratory tests.
  • Women of must practice medically acceptable from study treatment start until at least 30 days after the last dose of study treatment. Negative serum pregnancy test within 14 days before the first day of study treatment (not required for patients who are for at least 1 year or surgically sterilized). Study treatment should not be given to women who are breastfeeding.
  • Males who are sexually active must agree to practice medically acceptable barrier contraception while receiving study treatment and for 30 days after the last dose of study treatment.
  • Give written \& privacy authorization.

Exclusion criteria

Exclusion Criteria:

  • If there is a history of prior other than non-melanoma skin cancer, carcinoma in situ of the cervix, localized prostate cancer, or localized thyroid cancer, patient must be disease free for at least 5 years. Patients with other prior malignancies less than 5 years before study entry may be enrolled if they received treatment resulting in complete resolution of the cancer and have no current clinical, radiologic, or laboratory evidence of active or recurrent disease.
  • (HIV)-positive diagnosis with a of less than 100 mm3 or detectable viral load within the past 3 months, and receiving combination anti-retroviral therapy.
  • Diagnosis of virus, or virus with detectable viral load or immunological evidence of chronic active disease or receiving/requiring antiviral therapy.
  • Active central nervous system disease requiring treatment.
  • Active uncontrolled infection, underlying medical condition, or other serious illness impairing the patient's ability to receive protocol treatment.
  • Discontinuation of prior oral bexarotene due to an allergic reaction or treatment-related toxicity.
  • Major surgery within 2 weeks of planned start of treatment.
  • Conventional or chemotherapy or radiation therapy encompassing greater than 10% of bone marrow within 4 weeks prior to study treatment.
  • ECP, phototherapy with PUVA, or ultraviolet (UV) therapy within 2 weeks prior to study treatment.
  • Systemic within 3 weeks of study treatment, unless patient has been taking a continuous dose of no more than 10 mg per day of prednisone or equivalent for at least 4 weeks.
  • Initiation of or change in dosage of topical corticosteroids within 3 weeks of study treatment (topical steroid use within 3 weeks is allowed provided the strength and use has been stable for at least 4 weeks).
  • Investigational drugs, biologics, or devices use within 2 weeks prior to study treatment or planned use during the study.
  • Monoclonal antibody within 3 months without evidence of PD.
  • Use of oral retinoids, except bexarotene, within 4 weeks of study treatment or high-dose vitamin A (once daily multi-vitamin allowed).
  • Previous exposure to pralatrexate.
  • Uncontrolled hypercholesterolemia or hypertriglyceridemia.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Bexarotene (Targretin) & Pralatrexate (Folotyn)

    Bexarotene (Targretin): administered po qd. The initial daily dose of bexarotene will depend on the cohort to which each patient is assigned. Bexarotene will be self-administered except in patients who underwent plasma PK sampling on cycle 1, dose 1 and cycle 1, dose 3, at which time bexarotene was to be administered at the investigational site 1 hour (± 5 minutes) prior to pralatrexate administration. Pralatrexate (Folotyn): administered weekly via IV push over a minimum of 30 seconds up to a maximum of 5 minutes. One cycle is 4 weeks in duration consisting of weekly dosing of pralatrexate for 3 weeks followed by 1 week of rest. The initial dose of pralatrexate will depend on the cohort to which each patient is assigned.

    Drug: Pralatrexate Injection · Drug: Bexarotene Capsules · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

Interventions

  • Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride). 10 or 15 mg/m2, depending on cohort assignment. Dose reductions allowed for protocol-specified criteria. Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met.

    Also known as: FOLOTYN, PDX, Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin

  • 150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal. Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert. Administered daily until criteria for study treatment discontinuation per the protocol are met.

    Also known as: Bexarotene, Targretin®

  • Dietary supplementVitamin B12

    1 mg intramuscular injection Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).

    Also known as: Cyanocobalamin

  • Dietary supplementFolic Acid

    1-1.25 mg orally Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene).

    Also known as: Vitamin B9, Folate, Folacin

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT) Rate

    DLT rate is the number of patients experiencing a DLT divided by number of evaluable patients and it will be summarized by dose level.

    Time frame: Assessed weekly through cycle 1 (weeks 1-4)

Secondary outcomes

  1. Overall Response Rate (ORR)

    best overall response is the best response recorded from the start of treatment until PD. The objective response rate is the proportion of patients with a best overall response of either CR or PR and it will be summarized by dose level and overall.

    Time frame: Assessed after every 2 cycles (8 weeks) for the first 12 months, then every 4 cycles (16 weeks) until progression of disease.

  2. Number of Patients with Treatment-related Adverse Events (AEs) and Serious AEs (SAEs)

    (CTCAE) Scale, Version 4.0 for AE grading. * Grade 3 neutropenia lasting for ≥ 7 days or granulocyte colony-stimulating factor (G-CSF) administered. * Grade 3 thrombocytopenia. * Grade 3 treatment-related hyperlipidemia or hypothyroidism * Grade 3 study treatment-related non-hematologic toxicity

    Time frame: Recorded at all study visits: weekly (every 7 +/- 2 days) while on treatment and at safety follow-up (35 +/- 5 days post-last dose) or early termination visit (at time of withdrawal).

  3. Pharmacokinetic Parameters

    This was collected during the dose-finding stage of the study. PK sampling is not included in the cohort expansion.

    Time frame: Sampling through 24 hours post end-injection of pralatrexate in cycle 1 dose 1 (week 1) and cycle 1 dose 3 (week 3).

07

Study locations

5 sites
  • Stanford University School of Medicine
    Stanford, California 94305, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • University of Pittsburgh School of Medicine
    Pittsburgh, Pennsylvania 15213, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Ospedale Sant'Orsola - Policlinico Sant'Orsola
    Bologna, 40138, Italy
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2010
First posted
Jun 2, 2010
Start
Mar 2010
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Last update
Dec 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01134341
Responsible party
Sponsor
First posted
Jun 2, 2010
Start date
Mar 2010
Primary completion
Aug 2015
Completion
Aug 2015
Last update
Dec 18, 2019

Study contacts

Pankaj Sharma, MD
study director · Spectrum Pharmaceuticals, Inc
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pralatrexate · Bexarotene

Start the discussion